Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease.
Publication/Presentation Date
4-27-2021
Abstract
BACKGROUND: Factors responsible for poor sleep quality in patients with chronic obstructive pulmonary disease (COPD) includes the effects of medications. This study evaluates the effect of the inhaled triple therapy of budesonide-formoterol-tiotropium versus placebo-tiotropium on sleep quality in COPD patients.
METHODS: Twenty-three patients (11 [48%] males; age 55 [51-60, 48--5] years; body mass index [BMI] 25 [22-30, 18-40] kg/m
RESULTS: After 28 days, there was a significant 29% increase in the bedtime FEV
CONCLUSION: In patients with COPD, inhaled triple therapy with budesonide-formoterol-tiotropium as compared to placebo-tiotropium improves pulmonary function while preserving sleep quality and architecture.
Volume
8
Issue
2
First Page
219
Last Page
229
ISSN
2372-952X
Published In/Presented At
Krachman, S. L., Vega, M. E., Yu, D., Demidovich, J., Patel, H., Jaffe, F., Soler, X., Shariff, T., D'Alonzo, G. E., Chatila, W., Weaver, S., Daraz, Y., Cohen, S., & Criner, G. J. (2021). Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease. Chronic obstructive pulmonary diseases (Miami, Fla.), 8(2), 219–229. https://doi.org/10.15326/jcopdf.2020.0178
Disciplines
Medicine and Health Sciences
PubMedID
33610139
Department(s)
Department of Medicine
Document Type
Article